

Laten we gezondheidsdata beter inzetten



- ✓ Geef kracht aan jouw stem als patiënt door sterke onderbouwing
- ✓ Makkelijkere en betere gesprekken voeren met artsen
- ✓ Vergelijk met andere patiënten

Data gebruiken om ervaringen van patiënten mee te nemen in beslissingen over zorg

Lees meer op <https://health-outcomes-observatory.eu/>

of scan hier



H2O has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945345. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and Trial Nation and JDRF. www.ih.europa.eu

DISCLAIMER: this infographic reflects only the author's view. Neither IMI, nor EFPIA, nor the European Commission, nor the JU are liable for any use that may be made of the information it contains. The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It works to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI was the world's biggest public-private partnership (PPP) in the life sciences until its successor, the Innovative Health Initiative (IHI), was established in 2021. www.ih.europa.eu

Laten we gezondheidsdata beter inzetten



H₂O

HEALTH OUTCOMES
OBSERVATORY



- ✓ Geef kracht aan jouw stem als patiënt door sterke onderbouwing
- ✓ Makkelijkere en betere gesprekken voeren met artsen
- ✓ Vergelijk met andere patiënten

Data gebruiken om
ervaringen van patiënten
mee te nemen in
beslissingen over zorg

Lees meer op

<https://health-outcomes-observatory.eu/>

of
scan
hier



H2O has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945345. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and Trial Nation and JDRF. www.ih.europa.eu

DISCLAIMER: this infographic reflects only the author's view. Neither IMI, nor EFPIA, nor the European Commission, nor the JU are liable for any use that may be made of the information it contains. The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It works to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI was the world's biggest public-private partnership (PPP) in the life sciences until its successor, the Innovative Health Initiative (IHI), was established in 2021. www.ih.europa.eu

Beslissingen in de gezondheidszorg in handen van patiënten



H₂O

HEALTH OUTCOMES
OBSERVATORY



- ✓ Gebruik van patiëntgerapporteerde uitkomsten door meerdere belanghebbenden mogelijk maken
- ✓ Kwaliteit van zorg voor verschillende ziekten in verschillende landen beoordelen
- ✓ Een sterke patiëntencommunity bevorderen

Met en voor
patiënten

Lees meer op
<https://health-outcomes-observatory.eu/>



of
scan
hier



H2O has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945345. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and Trial Nation and JDRF. www.ihl.europa.eu

DISCLAIMER: this infographic reflects only the author's view. Neither IMI, nor EFPIA, nor the European Commission, nor the JU are liable for any use that may be made of the information it contains. The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It works to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI was the world's biggest public-private partnership (PPP) in the life sciences until its successor, the Innovative Health Initiative (IHI), was established in 2021. www.ihl.europa.eu